Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas

Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary... ORIGINAL ARTICLE Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas Agostinho Pinto Gouveˆa, MD, PhD,* Fernanda Milanezi, MD,w Sandra Jean Olson, MSc,z Dina Leita˜o, BSc,wy Fernando Carlos Schmitt, MD, PhD,wy and Helenice Gobbi, MD, PhD* chemistry may be used reliably as a primary methodology for Abstract: There is an increasing clinical demand for HER2 evaluating HER2; however, the use of polyclonal antibodies analysis in breast cancer, especially since the release of may not be adequate to assess HER2 overexpression. CB11, trastuzumab. The authors assessed the ability of immunohis- regardless of the manufacturer (Biogenex or Novocastra), tochemistry to detect HER2 overexpression in invasive mam- showed better concordance with FISH (kappa = 0.83) than mary carcinomas (IMC) using five antibodies. Paraffin- did the polyclonal antibodies. embedded samples of 86 IMCs (T2N0) were used to compare Key Words: breast cancer, HER2, C-erbB-2, immunohistochemi- the immunohistochemical overexpression of HER2 using two stry, fluorescence in situ hybridization polyclonal antibodies (HercepTest [DAKO] and A0485 [DAKO]) and three monoclonal antibodies (CB11 from two (Appl Immunohistochem Mol Morphol 2006;14:103–108) different laboratories, Biogenex and Novocastra, and 4D5 [Genentech]). All immunostainings were scored according to the FDA-approved HercepTest recommendations. The Her- rognostic and predictive factors http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas

Loading next page...
 
/lp/wolters-kluwer-health/selecting-antibodies-to-detect-her2-overexpression-by-orJpnQsXDt

References (41)

ISSN
1541-2016
DOI
10.1097/01.pai.0000155794.64525.11
pmid
16540740
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas Agostinho Pinto Gouveˆa, MD, PhD,* Fernanda Milanezi, MD,w Sandra Jean Olson, MSc,z Dina Leita˜o, BSc,wy Fernando Carlos Schmitt, MD, PhD,wy and Helenice Gobbi, MD, PhD* chemistry may be used reliably as a primary methodology for Abstract: There is an increasing clinical demand for HER2 evaluating HER2; however, the use of polyclonal antibodies analysis in breast cancer, especially since the release of may not be adequate to assess HER2 overexpression. CB11, trastuzumab. The authors assessed the ability of immunohis- regardless of the manufacturer (Biogenex or Novocastra), tochemistry to detect HER2 overexpression in invasive mam- showed better concordance with FISH (kappa = 0.83) than mary carcinomas (IMC) using five antibodies. Paraffin- did the polyclonal antibodies. embedded samples of 86 IMCs (T2N0) were used to compare Key Words: breast cancer, HER2, C-erbB-2, immunohistochemi- the immunohistochemical overexpression of HER2 using two stry, fluorescence in situ hybridization polyclonal antibodies (HercepTest [DAKO] and A0485 [DAKO]) and three monoclonal antibodies (CB11 from two (Appl Immunohistochem Mol Morphol 2006;14:103–108) different laboratories, Biogenex and Novocastra, and 4D5 [Genentech]). All immunostainings were scored according to the FDA-approved HercepTest recommendations. The Her- rognostic and predictive factors

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2006

There are no references for this article.